Health ❯ Healthcare ❯ Oncology
Drug Development Immunotherapy Patient Outcomes Pancreatic Cancer Precision Medicine Phase 3 Trials Phase 2 Trials Metastatic Colorectal Cancer Adverse Effects Lung Cancer Mantle Cell Lymphoma Patient Response Cancer Treatments Cancer Research Emerging Therapies Phase I Trials Metastatic Cancer Phase II Trials Bladder Cancer Metastatic Castration-Sensitive Prostate Cancer Trial Results Health-Related Quality of Life Silevertinib Targeted Therapies EGFR L858R-Mutated NSCLC Pediatric Oncology Meningiomas Abstracts ESMO Congress 2025 Non-Small Cell Lung Cancer DESTINY-Breast05 Trial Breast Cancer HER2-positive Breast Cancer Gastroenteropancreatic Neuroendocrine Tumors Combination Therapies VERITAC-2 Trial Treatment Efficacy Drug Treatments Innovative Therapies ADRIATIC Trial Phase III Trials Small Cell Lung Cancer IMforte Trial NRG-LU005 Study Regorafenib AI in Healthcare Glioblastoma Temozolomide KEYNOTE-B15/EV-304 Trial Drug Approval Muscle-Invasive Bladder Cancer NAPOLI 3 Study Gastric Cancer Melanoma Diffuse Large B-Cell Lymphoma Therapeutic Efficacy Patient Support Mitomycin (UGN-102) Non-Muscle-Invasive Bladder Cancer Adjuvant Treatment Trials Research Studies Gastroesophageal Adenocarcinoma Preclinical Models Cancer Immunotherapy Antibody-Drug Conjugates Treatment Sequencing Daraxonrasib RAS/MAPK Pathway Biosimilars Drug Efficacy RAS Initiative SERENA-6 Trial Randomized Trials
Want to see what podcasts are saying about this topic? Search across 145K+ podcasts. Explore Radar
The decision lets doctors switch an aromatase inhibitor to the oral SERD camizestrant after a blood test finds an ESR1 resistance mutation, with confirmatory trials required.
